FDA OKs Novel Enzyme Therapy for Rare Disease Phenylketonuria FDA OKs Novel Enzyme Therapy for Rare Disease Phenylketonuria

Pegvaliase-pqpz (Palynziq) helps address a significant, unmet need in phenylketonuria (PKA) patients whose blood levels of PKA cannot be controlled with current treatment options, the FDA says.FDA Approvals
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news